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Abstract 
The eight peer reviewed publications and 11 posters/abstracts of presentations 
which form the basis of this PhD, investigate the implementation of novel diagnostic 
tools and the application of these findings to identify possible therapeutic targets for 
management of varying stages of disease progression in common urologic cancers. 
The publications are drawn predominantly from basic urologic cancer research.  
Chapter One introduces the concept of translational medicine in urologic cancer 
research. Although clinical application is an integral part of urologic practice, 
medicine remains a scientific discipline and research forms an essential component 
thereof. The genomic profiling of multiple urologic cancers has allowed a more in 
depth appreciation into the intricacies of the disease. Investigating the genomic 
landscapes of urologic cancers has helped to identify driver gene alterations and 
their clinical implication on affected patients. Better understanding of disease 
development and progression may guide clinical decision-making, particularly in view 
of recent biomarker discoveries and targeted drug development for a more precision 
based approach to the oncological management of these patients.  
Chapter Two presents the implementation of translational tools in the uro-oncologic 
setting. Practical and financial challenges of routine collection and utilisation of 
research results in clinical practice remains a distant goal. Nonetheless the studies 
presented in this chapter explore the use of the basic research and the applicability 
of the results obtained.  
Chapter Three summarizes the discussion on the treatment-based application of 
translational medicine in urologic cancers. The aim to strive for a more 
comprehensive understanding of the urologic diseases we manage will guide 
precision treatment approaches to address the oncological needs of individual 
patients. 
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Preface 
Translational medicine in uro-oncology strives to understand the dynamics of cancer 
development, progression and treatment response in a bench to bedside approach. 
As part of this clinical application is essential in identifying treatment modalities that 
allow for individualised cancer care. The narrative of this thesis combines eight of the 
published peer reviewed articles and four of the abstracts that I have authored or co-
authored over a 10-year period. These articles are included in their full text format in 
the appendices. 
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Curriculum vitae 
I have been working as a specialist urologist in a clinical setting since completion of 
my training in Hamburg, Germany, in 2014. During our training, emphasis was 
mainly placed on the clinical aspects necessary to ensure a clear understanding of 
diagnosis, clinical management (conservative or interventional) and follow-up of 
urologic disorders to enable secure, independent decision-making for optimal patient 
care. Although clinical application is an integral part of urologic practice, medicine 
remains a scientific discipline and research forms an essential component thereof.  
 
As a trainee I was intrigued by research investigations undertaken by my peers and 
followed suit completing a prospective clinical study investigating the immediate 
vascular impact of cisplatin-based chemotherapy on young patients diagnosed with 
testicular cancer. As my interest migrated toward uro-oncology during the latter part 
of my specialist training, I applied for a onco-urology Fellowship in Vancouver, 
Canada. The fellowship was research based (with clinical duties) and I was able to 
nurture an interest in the genomic profiling of prostate and bladder cancer. Being 
part of a rising genomics laboratory team was a privilege. Investigating the genomic 
landscapes of these diseases helped to identify driver gene alterations and their 
clinical implication on affected patients. We were able to publish impactful peer 
reviewed studies to this extent. This work reiterated my desire to work as a clinician-
scientist, with the intent to better understand disease development and progression 
which may guide clinical decision-making, particularly in view of recent biomarker 
discoveries and targeted drug development for a more precision based approach to 
oncological management of these patients. 
 
I am currently working in the Department of Urology, at the University Hospital 
Southampton, with a particular interest in prostate and bladder cancers. The 
department creates a supportive environment for focused skills’ development and I 
believe our interests for research-based initiatives are ever growing, to address the 
needs and requirements of our patients. Ultimately a more comprehensive 
understanding of the diseases we manage will allow for greater individualised 
treatment approaches to address the oncological needs of our patients. 
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Chapter 1: translational medicine in urologic cancer 
 
1.1 Introduction 
 
In the vastly progressive field of biomedicine an interdisciplinary branch of 
translational medicine (TM) has recently emerged. The term, first coined in the 
1990’s, historically emphasized the concept of translating laboratory discoveries into 
practical clinical applications that would benefit the patient.1 Despite this fundamental 
step, the initial concept focused on unilateral benchside expertise driving clinical 
application, thereby missing crucial bedside feedback. This demonstrated clear 
limitations. Overall advancement in biomedical research became increasingly 
dependent on multi-disciplinary groups. The involvement of biomedical, clinical and 
basic scientists together with engineers and emerging technologies led to the 
evolution of a reciprocal appreciation for the benchside and bedside concept.2 
Returning clinical findings to research laboratories may redefine or enable new 
hypothesis-driven research efforts, resulting in potentially innovative discoveries.  
Potential pitfalls impacting on traditional bedside-to-benchside pathways present 
themselves when promising benchside discoveries fail to provide any significant 
bedside outcome. Notwithstanding, this two-way concept still misses an important 
aspect of the healthcare cycle: the community.3 The community represents healthy 
populations and/or patients as well as medical practitioners. All are vital to TM. 
Besides enriching TM with valuable input regarding background information on 
general health thereby enhancing existing tools and treatments, the community can 
promote involvement of patients groups and healthy volunteers in clinical trials. 
Finally, community involvement may also provide alternate sources of funding 
through grants, endowments and general fundraising activities. Financial expenditure 
often hampers research development particularly in social healthcare systems as 
funding is often limited to good basic healthcare coverage. Thus generating income 
outside of these structures is essential. 
The European Society for Translational Medicine (EUSTM) has therefore defined 
translational medicine as an interdisciplinary branch of the biomedical field supported 
by three main pillars: benchside, bedside and community. The goal of TM is to 
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combine disciplines, resources, expertise, and techniques within these pillars to 
promote enhancements in prevention, diagnosis, and therapies.3  
 
1.2 Use of translational medicine in urology 
 
Translational medicine in uro-oncologic disease research is focused on 
understanding underlying mechanisms of disease development and progression. 
The identification of new cancer pathways and their related interactions provides 
valuable information about disease evolution. Tools to identify patients with potential 
predisposition for early onset of urologic cancers may aid earlier surveillance or 
treatment with improved chances of cure. Furthermore, translational medicine offers 
a potential opportunity to research and identify processes that can stifle disease 
progression and action advanced disease on an individualised basis. The benefit of 
implementing newer and more innovative approaches to current treatment plans may 
improve patient outcomes and quality of life. 
A three-way approach to uro-oncological research focuses heavily on developing, 
advancing and implementing novel therapeutics and treatment paradigms in cancer 
patients. Clinical application gives clinician-scientists insights to response and new 
avenues to explore, driving renewed benchside development. Community-based 
application in the form of clinical trials aid in assessing expectations. 
 
1.3 Aims of this thesis 
 
This thesis presents several studies that demonstrate the diverse application of 
novel research-based tools in common urologic cancers. The application of these 
tools has improved our understanding of the dynamics of urologic cancers. As a 
result insight is gained into the clinical implications and invoke consideration for 
therapies that more readily address the causes than conventional treatment options 
may do alone. 
The studies featured in this manuscript are wide-ranging and besides focusing on 
localised and treatment naive metastatic disease, encompass metastatic treatment-
resistant urologic cancers as well. The translational tools implemented are diverse; 
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spanning medical devices, clinical impact assessments to minimally invasive blood 
tests investigating the genomic composition of cancer DNA as well as establishing 
surrogate blood markers to identify potential cancer patients at risk of conventional 
treatment complications.  
This thesis aims to emphasize the core principles of translational medicine in 
urologic cancer. Benchside discoveries aim to promote bedside application. The 
reimplementation of these discoveries expedite renewed studies to further develop 
tailored oncological management. 
 
Figure 1: Studies integrated into this thesis illustrating the diverse application of 
novel research tools in common urologic cancers 
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Chapter 2: Implementation of translational tools in uro-oncology 
 
During the past three decades, mortality has fallen substantially in an aging 
population (in high-income countries). This decrease is due to a historic change in 
the development of worldwide health status.4 Despite general improvements in 
health care, the incidence and mortality of urologic cancers, in particular those of 
bladder, prostate and kidney, vary significantly across the globe.5,6,7 Alarmingly the 
cumulative incidence of  kidney, bladder, and prostate cancers has risen by 2.5-fold 
to 2.1 million new cases worldwide from 1990 to 2013. The number of cumulative 
deaths from these malignancies increased by 1.6-fold in the same timespan. The 
contributory biological influence of gender, tobacco use and obesity likely impact on 
the incidence and outcomes of urologic malignancies.8  
 
Key to addressing a rise in incidence of malignancies and associated morbidity and 
mortality is understanding the evolving burden of disease in a maturing population 
when considering the differential outcomes in resource-limited settings. Prioritized 
research for these prevalent cancers is essential in unlocking complexities that may 
facilitate targeted health care policies. The 8 published manuscripts and 11 abstracts 
and presentations (Section 1) comprising this body of work demonstrate the 
implementation of novel translational medicine techniques to gain further insight into 
several common urologic cancers. 
 
Consideration must be taken to address morbidity of definitive treatment approaches 
in the management of uro-oncologic cancers. The risk of any procedure should not 
outweigh the potential benefit nor impact on quality of life to such a degree that 
would render it a justifiable liability. The consideration of cancer surveillance in small 
renal masses and certain localised prostate cancers has revolutionised our approach 
and has allowed patients to continue their daily lives unchanged. Nonetheless the 
psychological burden of untreated disease may propel some patients to desire a 
more definitive approach to the management of their disease. Thus the need for 
organ conservation, which aids in preserving function and quality of life, has led to 
the emergence of minimally invasive treatment modalities. 
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2.1 Minimally invasive treatment modalities 
 
Current onco-ablative techniques, including both the most established as well as 
novel minimally-invasive, focal techniques, include: 
Cryoablation which involves freezing the renal tumor to less than 20°C using liquid 
argon or nitrogen, followed by a thawing cycle, performed as a single or double 
freeze-thaw cycle, which causes tissue denaturation and destruction. Cryotherapy 
disrupts the cell membrane stability and protein synthesis, and causes direct cellular 
injury by formation of ice crystals which injure the intracellular structures.9,10 
Radiofrequency ablation which occurs by the transfer of high-frequency electrical 
current into target tissue culminating in thermal energy. Temperatures in excess of 
60°C cause tissue destruction through coagulative necrosis, fibrosis, and thermally 
induced vascular thrombosis. The conductive heat spreads to adjacent tissue, 
leading to tissue ablation.10,11,12 
Similarly high intensity focused ultrasound (HIFU) coagulative necrosis of treated 
tissue (most commonly prostate) is achieved by thermal ultrasound energy.13 
 
A recent study compared partial nephrectomy (PN) to RFA and cryoablation for renal 
lesions ⪬ 7cm in 1803 patients (1057 PN, 180 RFA, 187 cryoablation), found that for 
lesions less than 4cm, local recurrence-free survival was similar between all three 
techniques, however, metastasis-free survival was lower in the RFA group. Those 
patients who underwent PN for sub 4cm lesions had a statistically significantly higher 
overall survival when compared with ablative therapy (PN 95%, RFA 82%, 
cryoablation 88%). For lesions 4-7cm, PN and cryoablation again had similar local 
recurrence and metastasis-free survivals, however, PN offered significantly higher 
overall survival for these patients (PN 93%, cryoablation 74%).14 It is however 
important to emphasize that the higher overall survival in the PN group is reflective of 
a younger, less comorbid population with a better preoperative renal function.  
 
Comparative efficacy of focal therapy in treating clinically significant non-metastatic 
prostate cancer was published, demonstrating failure free survival was 99% at 1 yr 
and 88% by year five. For the entire cohort, the oncological outcome was reflective 
of a metastasis-free, cancer-specific, and overall survival at 5 years was 98% (95% 
CI 97–99%), 100%, and 99% (95% CI 97–100%), respectively. Functionally, patients 
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achieved complete pad-free urinary continence and none required more than 1 
pad/day.15 
 
Current trials investigating innovative technologies have emerged as is the case with 
vascular targeted photodynamic therapy (VTP) for the management of localised 
prostate cancer. This phase II trial induces focal ablation of tumor lesions through 
cell necrosis by damaging the tumor vasculature. VTP destroys targeted tissues 
using a photosensitizer (TOOKAD Soluble [WST11], STEBA Biotech) in association 
with a low-power near-infrared laser in the presence of oxygen. WST-11 absorbs 
light and transfers energy to oxygen molecules creating reactive oxygen species 
inducing local vascular occlusion and cell destruction. TOOKAD is applied 
intravenously and the illumination of the targeted area by transperineal optical fibers 
inserted under trans-rectal ultrasound guidance under general anesthesia.16,17 After 
a 3.5y standard care follow-up, successful focal ablation was documented for 75% 
i.e. 51/68 patients remained cancer-free in the treated lobe. The most common low 
grade side effects included erectile dysfunction (ED; n = 28), lower urinary tract 
symptoms (n = 14), and perineal pain (n = 9).18 Despite demonstrating potential 
clinical application, TOOKAD lacks FDA approval to date. 
 
Novel therapeutic drug delivery devices have also been considered for the focal 
management of localised oncological disease. The device acts as a reservoir for the 
designated drug as well as the delivery apparatus to provide controlled delivery of 
the drug to the affected area and hence reduce toxicity and the associated adverse 
events of systemic treatment.19 Examples include passive drug delivery implants that 
release drugs at predetermined rates by osmotic pressure 19,20, a porous 
membrane21, polymer degradation22, or a change in their surroundings such as pH or 
temperature variation22,23 with very limited or no dosing control i.e. over the rate and 
time of release of the drug. Alternatively a major benefit of an on-demand drug 
delivery apparatus is that the drug release can be switched on and off to suit a 
proposed treatment regimen but may later be adjusted if a relevant change in dosing 
is required as a result of an unexpected change in the condition of the patient.24 
Ideally an implanted device delivers the drug on-demand, regulated by an on/off 
mechanism while maintaining drug stability within the reservoir to enable individually 
tailored treatment regimes. Microelectromechanical systems (MEMS) have been 
12 
 
used to accurately regulate the dosage and time of drug release, however these 
mechanisms require a power source (batteries) with which to release the loaded 
drug. To address this limitation On-Demand™ therapeutics, for example, has 
developed a laser activated intravitreal drug reservoir for the treatment of ocular 
diseases20, magnetic actuation may offer another alternative for these devices. In a 
study comprising this thesis we hint at the capability of implanting a magnetically 
actuated drug delivery device, harboring docetaxel, into an animal model for 
treatment of localized prostate cancer. 20,25  
Results were in favour of the device: immunohistochemistry staining evaluating the 
extent of leukocyte infiltration exhibiting good biocompatibility and oncological 
efficacy as a sign of chronic inflammation demonstrated the device and the control 
subgroup displayed similar compatibility. Most affected by signs of chronic 
inflammation were the mice receiving subcutaneous docetaxel depot injections. 
Further histopathological interrogation of the device cohort comparatively 
demonstrated superior efficacy of cellular apoptosis and lack of cell proliferation than 
any other cohort. Oncologically, our device established comparable tumor growth 
rate suppression to subcutaneous docetaxel administration and only slightly inferior 
to intravenous docetaxel application with significantly less adverse events than either 
subcutaneous or intravenous treatment modalities. Multiple factors contribute to a 
decision regarding treatment options for patients with localised cancer, including 
patient age, comorbidities, extent and nature of the disease as well as functional and 
oncological outcomes. Magnetically actuated or microelectromechanical systems 
show promise in addressing those concerns well. This study in particular reflects 
upon the additional options novel clinical treatment approaches may offer for 
localized (prostate) cancer management in the future. 
 
2.2 Biomarkers to better characterise and treat urologic cancers 
 
Prognostic and predictive biomarkers have become a rapidly progressive branch of 
translational oncology in recent years. Comparatively, prognostic biomarkers provide 
information about the patient’s overall cancer outcome, regardless of therapy. A 
common prognostic biomarker in uro-oncology is the prostate specific antigen (PSA) 
for prostate cancer. The predictive biomarker on the other hand not only provides 
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information about the efficacy of a therapeutic intervention, it also offers a potential 
target for novel agents. In addition, predictive biomarkers may deliver insight into 
potential high risk patients. This may equip physicians with improved tools for 
selecting treatments for individual patients.  
 
Figure 2: Biomarker applicability26 
Biomarker Type 
 
       Usage 
 
 
 
 
In a clinical study encompassed in this manuscript we aimed to explore the 
pathogenesis of acute, peri-chemotherapeutic vascular events (including arterial 
occlusions, myocardial infarctions, and cerebral strokes) by investigating potential 
laboratory parameters associated with vascular disease in young healthy testicular 
germ cell cancer patients undergoing platinum-based chemotherapy.27 
Comparatively late onset cardiovascular risk including atherosclerotic disease, 
coronary artery disease, and myocardial infarction is well established in germ cell 
cancer survivors post platinum-based chemotherapy.28 The central finding in our 
study is the increase of von Willebrand Factor (vWF) during the course of cisplatin-
based chemotherapy and the subsequent normalization of this value within several 
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months after completion of treatment. This increase of vWF would suggest 
endothelial damage secondary to the chemotherapy with consecutive hyperactive 
coagulation to be the clue to the pathogenesis of associative acute vascular toxicity. 
The results do not conclusively predict for cardiovascular events, however, remind 
physicians to remain vigilant when administering platinum-based chemotherapy in 
this subset of oncological patients. 
 
Given that individual oncological diseases are heterogeneous in their molecular 
makeup and treatment responsiveness, this often results in the treatment of many 
patients with ineffective drugs, incurring of substantial medical costs for the 
treatment of patients who do not benefit and the conducting of large clinical trials to 
identify small, average treatment benefits for heterogeneous groups of patients. This 
may delay effective treatment in many cases. In oncology, new genomic 
technologies provide powerful tools for the selection of patients who require systemic 
treatment and are most (or least) likely to benefit from a molecularly targeted 
therapeutic.29 
 
Commonly these biomarker investigations are either tissue- or blood-based.  
Tissue samples for molecular genetic studies may be available in two main formats, 
either as fresh frozen samples or as formalin-fixed, paraffin embedded (FFPE) 
tissue.  
Tissue based investigations interrogate three types of macromolecule: 
DNA - despite a relative resistance to degradation, may be less instructive in a FFPE 
setting as formaldehyde fragments DNA, resulting in shorter, less informative 
fragments wherein mutations might be missed or conversely misinterpreted. 
RNA - is the most labile class of molecule. Functionally RNA generates molecular 
signatures dependent on the effect of the environment on tumor tissue. For example, 
RNA signatures of warm ischemia (the length of time devascularized tissue is at 
body temperature), cold ischemia (the length of time tissue sits at ambient 
temperature until stabilization by freezing or fixation) or even pre-operative diet (low 
vs. high protein content) have been generated, possibly influencing assessment of 
findings. 
Proteins - remain one of the most widely used biomarker assays in 
immunohistochemical localization and assessment of expression levels.30 
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Table 1: Potential prognostic or predictive biomarkers in prostate cancer.31 
Biomarker Source Clinical relevance 
Prognostic versus 
Predictive 
Metastatic status 
Clinical Number of bone 
metastasis (EOD), visceral 
metastasis 
Prognostic/Predictive 
Performance status 
Clinical ECOG performance status 
(0–4) 
Prognostic/Predictive 
Time to CRPC 
Clinical 
Time from ADT to CRPC Predictive 
Prior treatment Clinical Number of antiandrogens 
or steroid 
Predictive 
PSA Blood Protein specifically 
extracted from prostate 
gland 
Prognostic 
PSA kinetics Blood PSA decrease rate under 
treatment 
Prognostic 
Gleason score Tissue 
Pathological 
features strongly 
correlated 
prognosis 
Prognostic/Predictive 
Lactate 
dehydrogenase 
Blood 
Elevated by injuries and 
various disease including 
cancer 
Prognostic/Predictive 
Alkaline phosphatase Blood Elevated by cancer Prognostic 
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spreading to bones or liver 
Albumin Blood An index of nutritional 
status 
Prognostic 
Hemoglobin Blood Decreased by anemia Prognostic/Predictive 
Neutrophil-lymphocyte  
ratio (NLR) 
Blood 
Elevated NLR 
predicted poorer OS 
in various cancer 
patients 
Prognostic 
Testosterone Blood 
Ligand of AR 
associating 
prostate cancer 
proliferation 
Prognostic/Predictive 
Number of circulating 
 tumor cells (CTCs) 
Blood 
Increased number of 
CTCs associating with 
worse cancer prognosis 
Prognostic 
Androgen Receptor splice 
variants in CTC (esp. AR-
V7) 
Blood 
Correlating with poor 
response to ENZA and 
ABI but good response 
to Chemo 
Predictive 
Concentration of  
cell- free DNA (cfDNA) 
Blood 
Increased abundance 
of cfDNA associating 
with worse cancer 
prognosis 
Prognostic 
AR mutation and 
 copy number in cfDNA 
Blood Correlating with worse 
efficacy of ENZA and ABI 
Predictive 
Somatic DNA  
repair mutations 
Tissue 
Correlating with poor 
response to ADT, but 
good response to PARP 
Prognostic/Predictive 
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inhibitors 
Tumor mutational burden 
(TMB) 
Blood 
Elevated TMB 
is  association with 
response to Immuno-
Oncology 
Predictive 
ABI, abiraterone; ADT, androgen-deprivation therapy; AR, androgen receptor; cfDNA, cell-free DNA; CRPC, castration- 
resistant prostate cancer; CTC, circulating tumor cell; ECOG, Eastern Cooperative Oncology Group; EOD, extent of 
disease; ENZA, enzalutamide; mets, metastases; NLR, neutrophil-lymphocyte ratio; OS, overall survival; PARP, poly-ADP 
ribose polymerase; Pred, predictive marker, Prog, prognostic marker; PSA, prostate-specific antigen. 
 
Depending on which molecular analysis is deployed (DNA, RNA, proteins), frozen 
tissue samples are ordinarily preferred (however harder to come by as this requires 
a multidisciplinary approach to ensure timely preparation) over FFPE. In particular 
this is the case for RNA and protein analysis as FFPE samples often contain 
degraded RNA and non-native configurations of phosphorylated proteins. 
  
Given how heterogeneity of pre-analytical variables may impact on the results 
obtained, including analyte stability (which is different for different analytes i.e. DNA, 
RNA or protein), a period of warm and of cold ischemia, fixation time, tissue 
processing, sample storage time and storage conditions, as well as the invasiveness 
of real time tumor biopsies with associated complications are inevitable. In addition, 
a single biopsy sample may not represent the full tumor load's heterogeneity.32,33,34 
The urgency for minimally invasive investigations with similar detail was apparent. 
 
The development and rapid expansion of liquid biopsy in translational oncology have 
addressed this need. There are several sources of tumor material that can be 
assessed by liquid biopsy: cell-free or complexed nucleic acids including circulating 
cell-free DNA (cfDNA), of which a subset represent circulating tumor DNA (ctDNA), 
cell-free RNA (cfRNA), and circulating tumor cells (CTCs). CTCs represent intact, 
viable non-hematological cells with malignant features that can be isolated from 
blood.35 cfDNA is composed of small fragments of DNA that are not associated with 
cells or cell fragments, originating from apoptotic and necrotic tumor cells but also 
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from normal cells that are released into the bloodstream.36 Large scale ctDNA 
analysis of progressive cancer in view of cataloguing genetic mutations was first 
established in 2005 by The Cancer Genome Atlas (TCGA), supervised by the 
National Cancer Institute's Center for Cancer Genomics and the National Human 
Genome Research Institute.37 To date 33 cancers have been investigated.  
 
Interestingly, tumors containing ~50 million malignant cells release sufficient DNA for 
the detection of ctDNA in blood.38 In contrast, positron emission tomography—
computed tomography imaging generally detects tumors measuring no less than 7 to 
10 mm in size and containing ~1 billion cells.39 The liquid biopsy approach holds 
clear advantages over tissue biopsies: it is a source of fresh tumor-derived material, 
unhampered by preservatives. It gives real-time assessment  of the oncological 
disease status and sampling blood is minimally invasive, avoiding the complications 
of tissue-based approaches.40 Nonetheless a clear limitation of liquid biopsy is the 
amount of ctDNA shed may be lower than the detectable threshold. Previous studies 
have shown that ctDNA levels are dependent on location, size, and vascularity of the 
tumor and therefore lead to a difference in ctDNA levels among patients with similar 
disease.41,42 ctDNA is calculated as a percentage of the cell free DNA available and 
referred to as a fraction thereof. 
 
In this field of translational oncology, initial liquid biopsy studies focused on 
progressive, treatment-resistant metastatic disease. The aim was to ensure sufficient 
fractions of detectable ctDNA would be available for analysis. Multiple studies 
comparatively appraised liquid versus tissue biopsy aiming to establish correlative 
value or, ideally, to demonstrate the superiority of liquid biopsy. In fact a study 
investigating the concordance of circulating tumor DNA and matched metastatic 
tissue biopsy in prostate cancer identified somatic mutations and copy number 
changes that highly correlated with each other in the matched samples.43 
Interestingly in that study ctDNA sequencing revealed robust changes not present in 
the paired solid biopsy, including clinically relevant alterations in the androgen 
receptor and PIK3 pathways, similarly a liquid versus tissue biopsy study of 
metastatic gastrointestinal cancers showed the interrogation of the liquid biopsy 
samples, revealed clinically relevant resistance alterations and multiple resistance 
mechanisms not found in the matched tumor biopsy in 78% of cases.44 These 
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studies demonstrate the utility of liquid biopsy as an informative tool to assess the 
real time genomic landscape of metastatic cancer. The benefit of liquid biopsy lies in 
its minimal-invasive nature when compared to tissue-based investigations with 
similar genomic detail. 
 
To ensure an accurate read of the mutations of interest expected to be detected in a 
ctDNA analysis of a specific cancer, the coverage or depth of sequencing is 
important. Coverage/depth is defined as the number of unique reads that include a 
given nucleotide in the reconstructed sequence being investigated, thereby the 
actual empirical per-base coverage represents the exact number of times that a base 
in the reference is covered by a high-quality aligned read.45 Deep sequencing refers 
to the general concept of aiming for a high number of unique reads of each region of 
a sequence.46 The rationale for deep sequencing is, even though the sequencing 
accuracy for each individual nucleotide is high, the very large number of nucleotides 
in the genome means that if an individual genome is only sequenced once, there will 
be a significant number of sequencing errors. Furthermore, many positions in a 
genome contain rare single-nucleotide polymorphisms (SNPs). Hence to 
distinguish between sequencing errors and true SNPs, it is necessary to increase the 
sequencing accuracy even further by sequencing individual genomes a large number 
of times. We were able to demonstrate this principle using a targeted sequencing 
strategy capturing all exons of 72 metastatic castrate-resistant prostate cancer driver 
genes.47,48 We have previously demonstrated that this approach identifies over 90% 
of somatic mutations present in matched metastatic tissue in patients with ctDNA 
above 2%.43 More recently studies have shown that even lower fractions of ctDNA 
can be detected with relative accuracy.49,50 This immensely broadens the 
applicability of liquid biopsy and in particular ctDNA analysis as a stand-alone 
approach to interrogate the genomic landscape of (urologic) cancer. 
 
2.3 Cell models in translational oncology 
 
Although recent advances in genomic translational oncology have opened novel 
avenues of research, there is still a need for preclinical, bench-based cancer 
research. In particular, the peculiar capability of human cancer-derived cell lines to 
provide an indefinite source of biological material for experimental purposes has 
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reinvigorated efforts to exploit these lines for the distinct purpose of capturing geno- 
and phenotypic cancer biology and to test the therapeutic efficacy of anticancer 
agents.51,52 This is fundamentally demonstrated in a publication listed in this thesis in 
which sunitinib-conditioned renal cell carcinoma cell lines were interrogated for 
mechanisms of resistance.53 The study demonstrated high upregulation of Netrin-1 
with associative cellular and endothelial migration. Unfortunately silencing of Netrin-1 
did not resolve migratory tendencies of the resistant cells as was expected. The lack 
of clear conclusions is likely in part due to the cellular communicative complexities 
contributing to metastatic disease progression in treatment resistant disease which 
are not well represented by this two dimensional cellular model. Evidence shows that 
conventional 2D conditions (the extracellular matrix components, cell-to-cell and cell-
to-matrix interactions) that are important for differentiation, proliferation and cellular 
functions in vivo are lost.54   
3D cell culture systems are an evolutionary step forward as they exhibit these 
features that better reflect complex in vivo conditions.55 Cancer research involving 
studies on biomarkers, invasion, metastasis and tumor angiogenesis have been 
widely carried out with three dimensional models.56,57,58 
  
Provided with the challenges of preclinical research, the emergence of cancer 
mouse models is of utmost importance as they aim to explore the causal link 
between candidate cancer genes and carcinogenesis as well as to provide models to 
develop and test novel therapeutics in depth. Traditionally, immunocompetent and 
immunodeficient mice with syngeneic and xenograft tumors transplanted 
subcutaneously or orthotopically have been used.59 We demonstrated the use of 
subcutaneously xenografted PC3 cells in our mouse model investigating the 
biocompatibility and therapeutic efficacy of a magnetically actuated drug delivery 
device.25 Patient-derived xenografts (PDX) allow for individualised evaluation of the 
cancer being investigated. The PDX can serve as the foundation for a program of 
evidence-based personal oncology by facilitating the determination of the driving 
alterations before administering therapy to patients, i.e. PDX-bearing mice are 
treated with applicable drugs, and antineoplastic effects are measured. Only if a 
clear response is observed, is the agent administered also to the patient from whom 
the PDX was derived. 
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2.4 Prognosticators for overall survival in urologic cancer 
 
Despite the potential genomic profiling offers in terms of detailed insights into 
oncological disorders and the application of this knowledge toward targeted 
therapeutics, the appreciation for objective assessment of the patient outcomes 
within the setting of clinical trials is crucial to further treatment guidelines and 
standardisation of care for our patients. Driving the discovery of surrogate predictive 
markers in clinical trials will allow for timely outcomes and cost effective evaluation of 
results. Our retrospective analysis aimed to establish an adequate prognosticator for 
overall survival of prostate cancer patients that developed metastasis in the course 
of their disease and had progressed on to castrate resistant prostate cancer 
(CRPC).60 The study evaluated the impact of the time of occurrence of metastasis on 
overall survival. Three subgroups were formed for evaluation: 
1. Presentation with metastasis within three months of initial diagnosis (de-novo-
M);  
2. patients developing primary metastasis more than 6 months prior to castration 
resistance (CSPC-M) 
3. patients with newly diagnosed metastasis within 6 months of becoming 
castration resistant or thereafter (CRPC-M). 
Crucially de novo metastatic patients progressed to CRPC significantly earlier from 
diagnosis (median 1.85 years) than the other two groups, CSPC-M (median 7.27 
years) and CRPC-M (median 9.15 years), respectively. It is worth noting, however, 
that CRPC-M had the shortest median overall survival from the date of diagnosis of 
their metastases (2.94 years) compared to de-novo-M patients (6.41 years) and 
CSPC-M (7.01 years). Reflecting upon the results, relevant limitations include the 
lack of uniform follow up, the implementation of diverse imaging modalities to assess 
disease progression and variations in systemic oncological management. Despite 
these shortcomings, this study demonstrates time from diagnosis to CRPC (all 
patients) and time to metastasis (for CRPC-M and CSPC-M patients) are significant 
prognosticators of overall survival and are therefore valid surrogates in a study 
setting. Importantly there is no difference in survival between the groups once 
castration resistance was reached.  
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In fact, major trials such as SPARTAN 61 (evaluating apalutamide (ARN-509) in men 
with Non-Metastatic Castration-Resistant Prostate Cancer) and PROSPER 62 (a 
phase 3 study of enzalutamide in non-metastatic (M0) castration-resistant prostate 
cancer (CRPC) patients have already enrolled time to metastasis as a clinical 
endpoint. 
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Chapter 3: Clinical application of translational tools in uro-oncology 
 
3.1 Suitability of translational oncology in clinical practice  
 
Personalized therapeutics are already being implemented in oncology. Therapy 
selection based on the genomic characterization of individual tumors is 
demonstrated across several cancers. Treatment of women with breast cancer is 
often based on estrogen receptor status (HER2 amplification status and gene-
expression profiles) indicating the prognostic aggressiveness of the disease, with 
good response to targeted therapies when compared to conventional hormonal 
strategies.63 Similarly, the identification of BRAF mutations in melanoma have led to 
the introduction of BRAF- and MEK-targeted inhibitors with substantial benefit.64,65 
Equally in a phase II study Olaparib demonstrated favourable efficacy in patients 
with platinum-sensitive relapsed ovarian cancer with underlying BRCA 2 mutations.66 
In particular, BRCA1 and 2 mutations have been identified in familial breast, ovarian 
and prostate cancers with considerable clinical impact, encouraging the need for 
genetic counseling in suspected cases.67 Ultimately persons who are shown to have 
cancer-predisposition mutations in the germline may serve as sentinels for the 
identification of families at high risk.  
 
Understandably these developments have led to the consideration of screening high 
risk populations for underlying genetic mutations. In a landmark publication 
investigating the germline burden of DNA damage repair gene mutations in men with 
metastatic prostate cancer, 11.8% showed deleterious alterations in those genes.68 
This has clinical relevance as patients with inherited DNA damage repair gene 
defects have been shown to have associative early onset, clinically aggressive 
localized prostate cancer with cancer-specific mortality.69,70 The study by Pritchard et 
al did not discuss the clinical implications of their findings.70 In a publication enlisted 
in this thesis we investigated the distribution and clinical impact of DNA damage 
repair gene defects in a British Columbian population of men with metastatic castrate 
resistant prostate cancer.71 319 consecutive patients from our liquid biopsy program 
form the cohort for investigation. Germline mutations in DNA damage repair genes 
were present in 7.5% of cases, with BRCA2 mutations being the most common, at 
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two thirds of these. Importantly, clinical response to conventional androgen 
deprivation was poor, with progression to castration resistant disease at a median of 
11.8 months compared to 19 months in the wild-type cohort. Once started on 
traditional first line androgen targeting agents for castration resistance, median time 
to disease progression was 3.3 months, nearly half of the time reflective to the wild 
type correlative, suggesting poor response to androgen targeted therapies overall. 
Interestingly though, once metastatic castrate resistant disease was established the 
overall survival was similar at 29.7 months versus 34.1 months, respectively. In 
addition we investigated the presence of loss of heterozygosity of the intact BRCA 2 
allele. We were able to demonstrate in all 11 BRCA2 carriers with assessable 
somatic status (ctDNA fraction > 35%) displayed somatic hemizygous loss of BRCA2 
and RB1, and in 10/11 cases the somatic deletion removed the intact BRCA2 allele. 
Previously coinciding results had been described in the literature.68,72 Clinical 
applicability of LOH identification was shown in a recent phase II trial of olaparib for 
patients with mCRPC after chemotherapy, the median response of patients with 
DNA repair defects (germline and/or somatic) was 9.8 months73; a significant 
improvement on overall survival for patients with lethal disease. In fact, recently two 
PARP-Inhibotors (Olaparib and Rucaparib) have been granted FDA approval for 
implementation in this setting. Ultimately, therefore, it is feasible to contemplate that 
co-targeting with therapies that exploit defective DNA repair (eg, olaparib and 
carboplatin) may be a therapeutic approach in combination with androgen receptor-
targeted agents for metastatic castrate resistant prostate cancer patients with 
germline DNA repair mutations. However, this warrants clinical qualification.  
 
Despite progressive efforts to prolong overall survival in metastatic prostate cancer 
patients, the disease remains lethal. Interestingly, prolonged androgen deprivation 
therapy of patients with a history of prostate adenocarcinoma has led to transition of 
the tumor morphology to a small cell-like phenotype in some cases.74 Evidence from 
model systems suggests that under the selective pressure of prolonged androgen 
deprivation therapy or other androgen receptor-directed therapy, androgen receptor-
positive adenocarcinoma cells can acquire neuroendocrine features and small cell 
morphology.75,76 Notably, rearrangements of the ERG gene to androgen-driven 
promoters (e.g. TMPRSS2) are detected at approximately the same prevalence in 
treatment-related small cell prostate cancer as adenocarcinoma of the prostate. The 
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TMPRSS2- ERG gene fusion arises in the context of active androgen receptor 
signaling; therefore, while the fusion gene is often no longer expressed in 
transitioned small cell prostate cancer, it is indicative of an androgen -positive 
ancestral clone.77,78 Rarely do these cancers present as de novo metastatic disease. 
It is unknown whether de novo small cell prostate cancer is ancestrally distinct from 
treatment-related small cell prostate cancer or whether it too arises from 
adenocarcinoma, albeit in the absence of therapeutic pressure. Encompassed in this 
thesis is a study investigating the genomic landscape of de novo metastatic small 
cell prostate cancer. Eighteen patients were identified from which tissue based DNA 
extraction and sequencing of formalin-fixed paraffin-embedded (FFPE) tissues of 
specimens were interrogated to identify driver genes responsible for this rare 
prostatic cancer variant and consider possible targetable alterations for novel 
therapeutic agents.79 In our study at the DNA and RNA level, de novo small cell 
prostate cancer largely resembled treatment related small cell prostate cancer. 
Interestingly three novel characteristics were identified:   
1. De novo small cell prostate cancer did not harbor any androgen receptor gene 
alterations indicative of a castrate resistant prostate cancer ancestor exposed 
to androgen deprivation therapy.  
2. Our data suggests that patients with prostate adenocarcinoma harboring 
multiple ‘hits’ to TP53, RB1, PTEN and other tumor suppressors should be 
considered at risk of small cell prostate cancer transformation, even before 
exposure to androgen receptor-directed therapy.  
3. Surprisingly, nearly a third of our cohort presented deleterious biallelic 
alterations to homologous recombination repair (HRR) or mismatch repair 
(MMR) genes (MSH2 and MSH6) genes potentially enabling tumor 
suppressor loss. 
Commonly, given the expression of neuroendocrine markers chromogranin A and 
synaptophysin in this setting, patients are consequently managed similarly to other 
pulmonary and extrapulmonary small cell carcinomas, with platinum-based 
chemotherapy.80,81 Homologous recombination repair defects are linked to durable 
responses to platinum chemotherapy in prostate, breast and ovarian cancers,82,83,84 
which seems to be the underlying cause of efficacy. However given the genomic 
alterations identified in this study targeted treatments may be more applicable in a 
subset of these patients. The biallelic loss in DNA damage repair genes may offer 
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response to PARP inhibitors.85 While mismatch repair gene defects are associated 
with hypermutation and patient response to immune checkpoint blockade. Although 
this was a tissue-based study, future translational research should consider 
implementing liquid biopsy for ctDNA analysis which seems to be abundant in 
advanced patients with small cell-like histology.86 Liquid biopsy may offer a 
comparatively informative, yet minimally invasive approach to tissue-based 
interrogation, facilitating individualised cancer management for patients in real time. 
 
Recruited within this thesis is a milestone liquid biopsy study investigating the 
genomic landscape of de novo metastatic prostate cancer.87 Although assessible 
ctDNA fractions were expected, given the extent of disease at diagnosis. 
Improvements in deep sequencing to our previous studies was encouraging to note. 
We were able to perform liquid biopsy sequencing in 52/53 patients in our study (the 
threshold for ctDNA detection was 0.5%). Comparative tissue was available in 48 
cases. The concordance for mutation detection in matched samples was 80%. 35/53 
patients had their ctDNA collected before initiation of conventional androgen 
deprivation therapy. It was determined that the ctDNA fraction available in those 
patients with androgen deprivation therapy prior to ctDNA collection was significantly 
lower than in the treatment-naive cohort (59% of patients with a median of 1% 
versus 74% and 11% respectively), although ctDNA fractions varied strongly among 
patients (untreated range 0-84% and 0-51% in the treated subgroup). Patients with 
visceral metastasis present with the highest ctDNA burden. The comparative ctDNA 
and tissue investigations revealed similar genomic alterations (TP53; DNA damage 
repair gene defects, especially BRCA 2; CDK12) as in metastatic treatment-resistant 
disease, albeit without the androgen receptor gene alterations seen in progressive 
prostate cancer. 
Important conclusions from this study are: 
1. ctDNA provides additional information to a prostate biopsy in men with de 
novo mCSPC, but androgen deprivation therapy rapidly reduces ctDNA 
availability  
2. Primary tissue and ctDNA share relevant somatic alterations, suggesting that 
either is suitable for molecular subtyping in de novo mCSPC  
3. The optimal approach for biomarker development should utilize both a tissue 
and liquid biopsy at diagnosis, as neither captures clinically relevant somatic 
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alterations in all patients given that ctDNA or prostate biopsy alone was 
insufficient in 19 cases (36%). 
 
Likewise the need to implement minimally invasive, explorative investigations to 
analyse  the genomic landscape of several other urologic cancers is underway.  
The genomic evaluation of cancers in the several publications submitted in this 
thesis demonstrate not only the novelty, but the applicability of ctDNA sequencing 
across a spectrum of urologic cancers.71,79,87,88 In the case of metastatic bladder 
cancer platinum-based chemotherapy has been considered as the gold standard for 
first-line treatment.89 However the immunogenic nature of the disease has offered 
new treatment avenues to exploit. Several trials have led to the approval of immuno-
oncogenics to be used in as a cisplatin-alternative, albeit patients are required to 
have an adequate Programmed Death-Ligand 1 (PD-L1) status [KEYNOTE 361 
(ClinicalTrials.gov identifier: NCT02853305), IMvigor130 study (ClinicalTrials.gov 
identifier: NCT02807636)]. 
 
Upregulation of PD-L1 may allow cancers to evade the immune system. Several 
novel agents either inhibit the antigen PD-L1 or its receptor counterpart PD-1. 
Despite these advances, liquid biopsy analysis of metastatic bladder cancer is 
underexplored. We designed a study in which we applied a combination of whole-
exome sequencing and targeted sequencing across 50 bladder cancer driver genes 
to plasma cell-free DNA from 51 patients with aggressive bladder cancer, including 
37 with metastatic disease88. In order to ensure robust mutation calling, the ctDNA 
threshold for detection needed to be ≥ 2% of the total cfDNA available. While the 
majority of patients with metastasis (24/37 patients) were above this threshold, only 
14% of patients with localized disease had adequate ctDNA proportions. 
 
Twelve percent of estimable samples had evidence of genome hypermutation. We 
were able to reveal an aggressive mutational landscape in metastatic bladder cancer 
with 95% of patients harboring deleterious alterations to tumor suppressor genes 
(TP53, RB1, or MDM2) and 70% harbor a mutation or disrupting rearrangement 
affecting chromatin modifiers such as ARID1A. Interestingly the team I was a part of 
identified targetable alterations in MAPK/ERK or PI3K/AKT/mTOR pathways, offering 
administration of novel drug agents.90,91,92 The study also identified a novel FGFR3-
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ADD1 fusion not previously described. Important therapeutic conclusions that can be 
drawn from implementing ctDNA analysis in this setting are: 
1. We identified TSC1/TSC2 alterations which are reported to confer sensitivity 
to the mTOR inhibitor everolimus 
2. Hypermutation in bladder cancer is amenable to checkpoint inhibitors i.e. PD-
1 and PD-L1 inhibitors 
3. Aberrant PI3K/AKT/mTOR pathway alterations seen in a large proportion of 
our patients may suggest opportunities for testing of AKT inhibitors such as 
MK2206 that has previously demonstrated activity in BCa cell lines93 
4. Mutations in DNA repair genes raise the possibility that ctDNA profiling may 
also help guide implementation of cisplatin-based chemotherapy more 
precisely 
 
There is certainly mounting evidence that tumor subtypes and distinct somatic 
alterations can influence patient response to existing and novel therapies in 
advanced bladder cancer. As the arsenal of targeted and immunotherapies 
continues to grow, it is imperative that biomarker development keeps pace to guide 
their implementation. Our results show that analysis of circulating tumor DNA from 
the plasma of patients with metastatic BCa captures the somatic mutational profile in 
most patients. ctDNA profiling can form a practical tool for real-time patient 
stratification, and thereby avoid the need for tissue biopsy or interrogation of 
potentially less relevant archival tissue. 
Finally, it is important to highlight we observed high total cfDNA yields in patients 
receiving chemotherapy, in both the localized and metastatic setting, however this 
was not accompanied by increased (or any) circulating tumor DNA in most 
instances, suggesting elevated non-malignant cell death in the wake of systemic 
cytotoxic therapy. Therefore careful consideration should be given to the timing of 
liquid biopsy analysis. Future studies will need to consider appropriate time intervals 
for liquid biopsy investigation to maximise potential ctDNA availability. 
 
3.2 Augmenting clinical oncological guidelines through translational urology 
 
The proven benefits of personalised oncology in the metastatic setting with the 
advancement of genomic profiling, including the implementation of minimally 
29 
 
invasive techniques such as liquid biopsy, have generated interest in the 
assessment of genomic complexities in localised disease as well. Understanding the 
landscape of localised prostate and bladder cancer, in particular, may offer insights 
into the nature of the disease with particular consideration for disease progression 
and disease specific mortality. Ideally the aim would be to identify patients at 
particular risk of disease recurrence (for bladder cancer) and progression (both 
bladder and prostate cancer) that warrant more definitive treatment options including 
surgery or radiotherapy with curative intent. Overtreatment, particularly for patients 
with non-aggressive prostate cancer, is a particular concern, as major interventional 
procedures harbor risks and complications that may outweigh the benefit of 
treatment. Risk stratification is crucial in developing individualised oncological 
management. 
 
In the case of non-muscle invasive bladder cancer, there are several factors that 
contribute to the risk of recurrence and progression to muscle invasive disease 
(which in healthy individuals requires neoadjuvant chemotherapy and cystectomy), 
including number of tumors, tumor size, rate of recurrence, tumor grade and 
staging.94 Follow-up requires regular outpatient clinic appointments involving a 
cystoscopy under local anaesthetic. This is burdensome on many patients. As some 
recurrent bladder cancers are not well visualized on white light cystoscopy, urine 
cytology is sometimes added to aid diagnosis. Cystoscopy advancements that 
include blue light and narrow band imaging may prove additionally useful. Recent 
urine-based biomarker testing shows promise. Particularly when interrogating a 
simple urine sample may be sufficient when discerning recurrent disease. Ideally this 
may avoid the need for repeat cystoscopy altogether. Phase III-IV biomarkers 
include: 
1. Nuclear matrix protein 22 (NMP22): Nuclear matrix proteins are a structural 
part of the cell nucleus and provide support for the nuclear shape. A member 
of this family, NMP22, has been found to be elevated in malignant urothelial 
cells compared to normal urothelium95 
2. Bladder tumor antigen (BTA): Bladder tumor antigen (BTA) tests detect the 
presence of basement membrane factors in the urine, which are released 
from tumor cells during stromal invasion96 
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3. ImmunoCyt/uCyt+: The ImmunoCyt test is an immunocytological assay 
based on the microscopic detection of tumor cell antigens by 
immunofluorescence96,97 
4. UroVysion (FISH): UroVysion is a multicolor fluorescence in situ hybridization 
(FISH) containing probes to the centromeres of chromosomes 3, 7, 17 and 
the 9p21 locus (P16 tumor-suppressor gene)98 
 
There are several other urine based-tests currently under investigation. 
Unfortunately  none of the tests to date offer a negative predictive value (NPV) 
together with satisfactory sensitivity and specificity in this setting to be used as a 
stand-alone option for monitoring disease recurrence (NPV range 74-93%, sensitivity 
50-85% and specificity 46-93%).99 Importantly cases of non-muscle invasive bladder 
cancer with higher grade disease require BCG instillation therapy to reduce the risk 
of recurrence and progression.94,100 In a significant step toward realisation of 
implementation regarding these non-invasive biomarker tests, the American Urology 
Association (AUA) guidelines have stated clinicians may use biomarkers to assess 
the response to intravesical BCG (UroVysion® FISH) and adjudicate equivocal 
cytology (UroVysion® FISH and ImmunoCyt®).101 
 
Localised prostate cancer risk has been stratified using the D’Amico scoring system 
for more than the last two decades.102 It is important to note that the classification 
assesses the risk of biochemical (PSA) recurrence of disease following radical 
treatment for localised prostate cancer. Importantly though, this risk stratification 
does not assess prostate cancer specific mortality. When considering offering 
definitive treatment options to patients, it is important to assess the impact the 
disease will have on the overall survival of the patient. Overtreatment is a concern, 
especially when weighing risk and benefit. Two tissue-based genomic tests have 
been developed to aim to address these concerns.  
Prolaris® is a 46 gene RNA-based signature to predict prostate cancer specific 
mortality from tissue biopsy and radical prostatectomy specimens.103 Prolaris® has 
demonstrated significant prediction for high risk disease, biochemical recurrence 
post radical prostatectomy and metastatic progression.104,105 In addition, two studies 
surveying clinical decision-making of urologists with the additional results from 
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Prolaris® to their disposal have led to divergence from the initial arrangements.106,107 
The impact of these altered decisions await evaluation. 
The Decipher test consists of 22 RNA expression based genomic markers.108,109 
Decipher was independently predictive of metastasis and prostate cancer specific 
mortality.110,111 Importantly in the post-prostatectomy setting, Decipher has been 
evaluated for its ability to inform decisions regarding adjuvant and salvage radiation 
therapy.112,113 To determine clinical utility in the post-operative setting, 
PRO_IMPACT is a multi-institutional prospective study to assess clinical decision-
making and patient-reported outcomes after Decipher testing (NCT02080689). 
The OncotypeDx prostate biopsy test (17 gene panel) calculates a genomic 
prostate score (GPS) based on genes from 4 different pathways involved in prostate 
cancer).108 Unlike Prolaris® and Decipher, OncotypeDx was designed for use with 
biopsy tissue and does not have a commercially available test for post-prostatectomy 
risk stratification.114 Clinical utility studies indicate that OncotypeDx results may also 
influence decisions about patient management. Badani et al. reported that 18% of 
recommendations between active surveillance and treatment changed as a result of 
OncotypeDx and that clinicians also reported the results increased their confidence 
in decisions.115 
Despite all tests showing clinical promise, their exact role in localised prostate 
cancer remains uncertain. The AUA Guidelines mentions these biomarkers, 
however has refrained on making recommendations at this time as to their 
implementation in clinical practice. 
 
As discussed previously in this chapter with the recent demonstration that men with 
castration resistant prostate cancer and mutations of DNA damage repair genes 
(BRCA mutations) respond favorably to PARP inhibitors, there has been great 
interest in determining who should be tested for mutations and how the presence of 
mutations should alter therapeutic approach.71,116 The authors, including our own 
study encompassed in this thesis, assert that these men might be considered for 
earlier alternative therapy but it is unclear what therapy that should be and when it 
should be considered. Certainly in recognition of castration resistance alternative 
approaches may be warranted. The incidence of inherited DDR gene mutations has 
led to the National Comprehensive Cancer Network (NCCN) guidelines, now 
recommending germline testing for all men with metastatic prostate cancer.117 This 
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recommendation reflects a significant shift in the clinical applicability of translational 
uro-oncology and cements the need for continued research. 
 
Genomic profiling of urologic cancers has led to clinically significant discoveries 
which in turn have driven the reconsideration of recommendations regarding clinical 
practice, as has been partially reflected upon in this thesis. Moreover, despite the 
fact that research of this nature is costly and time consuming, the need for 
understanding the genomic complexities of urologic cancers has compelled clinician-
scientists to expand clinical trials investigating outcomes of targeted drugs by 
interrogating the genomics of those participants as well. A study by Annala et al 
demonstrates the application of liquid biopsy in treatment-naive metastatic prostate 
cancer patients enrolled in a Phase II cross-over trial comparing androgen receptor 
targeted agents Abiraterone and Enzalutamide.118  By leveraging plasma specimens 
collected in this large randomized trial, they are able to report the relative impact 
common circulating tumor DNA alterations have on patient response to the most 
widely used therapies for advanced prostate cancer. They were unable to observe 
evidence for differential efficacy between abiraterone and enzalutamide within any 
genomic or clinical subgroup, nonetheless the study showed only deleterious 
alterations in homologous recombination repair genes (BRCA2 or ATM) and TP53 
remained significantly associated with shorter time to progression of disease. Only 
two patients with mismatch-repair gene mutations were identified with both 
responding poorly to either targeted agent. Androgen receptor gain was not 
significantly associated with shorter time to progression after adjustment for ctDNA 
presence and clinical prognostic factors. It also did not impact on treatment 
response. However androgen receptor mutations were associated with treatment 
resistance. Key limitations include the exploratory nature of the analyses (in the 
absence of a prospective analysis plan) given only 115/202 patients had sufficient 
ctDNA for genomic evaluation, which prevented the researchers from assessing the 
clinical relevance of differing combinations of genomic alterations, and whether any 
specific combinations may be associated with complete lack of benefit from 
abiraterone or enzalutamide. Nonetheless this pioneering study reiterates the 
continued need for integration of novel diagnostics techniques with established clinic 
research to progress our understanding of the cancers we manage and the impact 
this may have on our patients.  
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3.3 Barriers hampering the clinical implementation of translational uro-
oncology 
 
Given the major potential ctDNA analysis offers, application has been found in 
several subsequent oncological settings as is reflected in the table below.119 
 
Table 2: Applications of ctDNA in cancer diagnostics119 
ctDNA Application Summary 
Prognosis 
determination 
• Absence of ctDNA after surgery is associated with a much better prognosis 
and smaller chances of relapse, nonetheless timing of the liquid biopsy may 
affect ctDNA availability and thus mask potential recurrent disease 
• Prognosis determination aids in selecting aggressiveness of treatment as well 
as determining the necessity for adjuvant therapy; patients at high risk of 
relapse could receive targeted treatment, while low risk patients are spared 
unnecessary chemotherapy 
Monitoring  
for  
treatment 
efficacy/relapse 
• ctDNA can be analyzed through a blood test; this ‘liquid biopsy’ can be 
repeated more often, enabling consistent monitoring of response to treatment 
• Raised ctDNA concentrations or increased number of mutations indicate 
treatment failure/relapse earlier than clinical relapse 
Selection  
of  
treatment 
• Sequencing the ctDNA informs choice of therapy to target specific mutations 
• Traditional tumor biopsies only allow for the analysis of a certain part of the 
tumor, which ignores intratumor heterogeneity, while ctDNA analysis provides a 
more holistic view of the tumor to inform more targeted treatment 
Tumor 
size/disease 
burden 
• Larger amount of ctDNA in blood correlates with advanced tumor stage/greater 
metastatic burden 
• Blood testing does not carry the risk of radiation exposure or poor accuracy of 
imaging; ctDNA can provide a snapshot of disease burden, which can be 
repeated more often than imaging or traditional biopsies 
Detection in 
asymptomatic 
individuals 
• Most studies show poor sensitivity, especially for early stage tumors 
• For small tumors, there is not enough ctDNA present to allow for an accurate 
test result 
• However, reliable ctDNA tests for early diagnosis would allow for early 
intervention and curative surgery and higher cure rates 
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Despite these advances, many avenues remain entirely unexplored whereas some 
have partially been investigated. The intricacies of the genomic pathways underlying 
urologic cancers are plentiful. This was clearly demonstrated by our study 
investigating the role of netrin-1 in sunitinib-resistant metastatic renal cell carcinoma 
cell lines. Since the downregulation of netrin-1 has shown to reduce metastasis or 
tumor growth in multiple cancers, our study sought to investigate whether netrin-1 is 
also a promising target in mRCC. Unfortunately we did not show a reduction in 
migration or cell viability in our cell lines after netrin-1 silencing. Hence other factors 
besides, netrin-1, are contributory to metastatic disease progression and sunitinib 
resistance in renal cell cancer.53 
 
Similarly research into the molecular subclassification of bladder cancer has led to 
several groups publishing multiple classification variants as reflected by the figure 
below. 
 
Figure 3: Molecular subtypes of bladder cancer, stratified by various study groups  
 
Color code: Purple = NEURAL; dark blue = LUM; green = PAP; orange = HER2L; red = SCC; light blue = MES. Ba/SCC = 
basal/squamous-cell carcinoma-like; Ba-Sq = basal-squamous; BOLD = bladder carcinoma subtypes of large meta-cohort 
database; CL,= claudinlow; diff. = differentiation; ECM = extracellular matrix; GU = genomic unstable; HER2L, HER2-like; 
LICAP = Leeds Institute of Cancer and Pathology; Lpapillary = luminal-papillary; Lum = luminal; LUM = luminal-like; Lum-inf = 
luminal infiltrated; LUND = Lund University; MDA = MD Anderson Cancer Center; Mes, mesenchymal; MES = mesenchymal-
like; MIBC = muscle-invasive bladder carcinoma; Neu = neuronal; NEURAL = neural-like; NMIBC = nonmuscle-invasive 
bladder cancer; PAP = papillary-like; SC/NE = small cell/neuroendocrine; TCGA = The Cancer Genome Atlas Network; UBC = 
University of British Columbia, UNC = University of North Carolina; Uro = urobasal 
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Understandably a better appreciation for the genomic profile of the disease aids to 
discern potential high risk cancer with the peril of recurrence and in particular 
progression. These critical studies have highlighted the complexities of the disease 
and the difficulty in identifying clear denominators for subclassification. The most 
recent and thorough investigation to date was published by Tan el al (Figure 3).120 
This study identified six bladder cancer subtypes, similar to the TCGA findings. 
Particularly interesting was that neural-, mesenchymal- and squamous-cell-like 
subgroups are predominant in progressive bladder cancer involving the muscular 
layer of the bladder with a comparatively worse overall survival. Although these 
studies provide insightful information correlative to clinical outcome, it remains 
difficult to envision clinical application in the near future with clear recommendations 
by governing clinical bodies as to implementation due to their underlying divergent 
nature. 
 
Equally our magnetically actuated drug delivery study is another example of 
progressive advancement of translational medicine in an oncological setting.25 
However the trial presented clear limitations as to the potential applicability in a 
clinical setting. Despite the fact that biocompatibility and efficacy were proven, 
obvious constraints of the study were the small cohort sizes (limited by the number 
of devices), a lack of variable doses of docetaxel in the device and in the 
comparative treatment arms to more accurately assess treatment efficacy. Moreover, 
treatment initiation and the tumor measurement time points needed to be adjusted 
with treatment initiation commencing earlier and the measurements performed at 
more regular intervals. Finally, the orientation of the aperture of the device toward 
the tumor and the angle of the actuating magnet are crucial for delivering the 
optimum dose of docetaxel accurately to the site of interest. Despite these 
shortcomings the feasibility of a device of this nature was discussed in a review 
article published in Nature Reviews.121  
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3.4 Future endeavours of translational uro-oncology 
 
This thesis has demonstrated the manifold capabilities of translational uro-oncology.  
Several of the studies reflected upon in this manuscript have demonstrated clinical 
applicability. Others show promise for future successes. The challenge lies in 
implementing the current knowledge to gain further insight to overcome the 
limitations of previous investigations.  
Liquid biopsy has proven its worth as a minimally invasive technique, applicable in a 
multitude of circumstances: 
1. Interrogating localised cancer by means of tissue and urine based tests to risk 
stratify patients diagnosed with common urologic cancers 
2. Discovering the landscape of treatment-naive advanced cancers to appreciate 
the genomic profiles of disease 
3. Mapping the landscape of advanced oncological disease offering the real time 
assessment of treatment response 
4. Application of genomic profiling in ongoing drug trials to discern non- and low 
responders better and to offer a more tailored approach to their care. 
Future endeavours should aim to continue the progress made to date. Several liquid 
biopsy studies (especially patented commercially available genomic panels) are 
cost-intensive and do not allow for routine clinical application. These investigations 
should be completed in a trial setting. This has been demonstrated by the reiteration 
of the AUA guidelines regarding tissue-based genomic biomarkers for localised 
prostate cancer. As per the current guidelines, biomarkers have not shown a clear 
role in the selection of candidates for active surveillance and are not necessary for 
follow up. These tests are in their infancy, however have drawn the attention of 
urologists as progressive development and may find use in the future. 
 
Recently, Zhao and collaborators developed and validated the Decipher Post-
Operative Radiation Therapy Outcomes Score (PORTOS).122 PORTOS is a 24 gene 
predictor of response to postoperative radiotherapy for prostate cancer. The score is 
not prognostic of metastatic outcome when no radiation therapy is utilized but is 
highly predictive of metastatic progression if adjuvant or salvage radiation is used, 
with high PORTOS scores being associated with a 7-fold reduction in metastatic 
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progression among men receiving postoperative radiation. This exemplifies the 
progression of development. 
 
At the University of California, Davis, with the Serial Patient Derived Xenograft 
Models to Eliminate Cancer Therapy Resistance Trial (SPIDER) is underway. This 
will enable tailored patient stratification strategies, potentially identifying novel 
predictive biomarkers and can uncover new biology not hypothesized previously. 
Applicability has been demonstrated by Hidalgo et al where targeted treatment was 
introduced to patients once modulated drug therapy successes were achieved in 
their corresponding PDX models.123 The mouse model driven drug delivery device 
study discussed in this thesis broadly reflects upon its utility.25 
 
The examination of potential biomarkers at the RNA, DNA or protein level by 
interrogating tissue, blood and other bodily fluid is guiding cancer research and 
clinical oncology increasingly towards molecularly directed therapy. Patient derived 
xenografts are an important additional tool in translational medicine for drug testing 
and biomarker development as the PDX provides a model system that recapitulates 
patient disease with the highest integrity. 
 
The tri-modal applicability of translation oncology in common urologic cancers is well 
described within this thesis. Progressive benchside research has proven useful in 
understanding of molecular dynamics in cancer progression. The identification of 
several novel biomarkers has found bedside utilisation with predictive and prognostic 
value in guiding oncologic management. In particular, the minimally invasive liquid 
biopsy analysis has proven to be an invaluable tool to this extent. Both the 
generalised application of biomarker findings leading to guideline considerations and 
alterations, as well as the implementation thereof in randomised clinical trials reflects 
upon the communal component constituting the third pillar of translational medicine.  
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Conclusion 
 
This body of work reflects the essence of translational medicine in common urologic 
cancers. The striving to advance the understanding of cancer dynamics whether in a 
localised or progressive state aids the identification of biomarkers and actionable 
targets for implementation in the clinical setting. From the magnetically actuated drug 
delivery device, offering a novel alternative in the management of localised disease 
to the minimally invasive liquid biopsy studies interrogating circulating tumor DNA in 
advanced urologic cancers for genomic alterations that may offer a better 
understanding of the underlying disease and possible targetable mutations and the 
search for biomarkers to identify high risk patients susceptible to acute vascular 
toxicity peri-chemotherapy, this research aims to improve an individualised approach 
to cancer care. Despite a degree of detail discussed in this manuscript with coverage 
addressing several fields within translational uro-oncology, truthfully it only offers a 
mere glimpse into the sheer magnitude of what translational medicine has to offer in 
our discipline. Ongoing and future translational endeavours strive to investigate more 
of the intricacies cancer research faces with the shared goal of improving cancer 
care for our patients. 
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